The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Danchenko I.Yu.

Vagner Perm State Medical University

Baidina T.V.

Vagner Perm State Medical University

Kuklina E.M.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Trushnikova T.N.

Wagner Perm State Medical University

Nekrasova I.V.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example Sema4D and CD72

Authors:

Danchenko I.Yu., Baidina T.V., Kuklina E.M., Trushnikova T.N., Nekrasova I.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2): 63‑71

DOI: 10.17116/jnevro201911910263

Read: 5038 times

Download PDF (RU)
Contact the author
Table of contents

RELAPSING-REMITTING MULTIPLE SCLEROSIS: CLINICAL AND IMMUNOLOGICAL ASPECTS OF THE PATHOLOGY ON THE EXAMPLE SEMA4D AND CD72
RELAPSING-REMITTING MULTIPLE SCLEROSIS: CLINICAL AND IMMUNOLOGICAL ASPECTS OF THE PATHOLOGY ON THE EXAMPLE SEMA4D AND CD72

To cite this article:

Danchenko IYu, Baidina TV, Kuklina EM, Trushnikova TN, Nekrasova IV. Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example Sema4D and CD72. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2):63‑71. (In Russ.)
https://doi.org/10.17116/jnevro201911910263

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Biomarkers of athe­rothrombotic and cardioembolic subtypes of acute ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):20-26
The use of algi­nate plates with a complex of anti­microbial peptides and cyto­kines after surgical inte­rventions on periodontal tissues as a prevention of early postoperative complications. Stomatology. 2024;(5):19-23
Local cyto­kine profile of the endo­metrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peri­pheral blood mono­nuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54
The rela­tionship between inflammatory markers, fati­gue, and effort-based deci­sion-making in patients at clinical high risk for psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):85-91
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
Inflammatory aging. Part 1. The principal biochemical mechanisms. Russian Journal of Preventive Medi­cine. 2024;(12):145-150
Immu­nomodulatory therapy in the postoperative period in chro­nic puru­lent otitis media. Russian Bulletin of Otorhinolaryngology. 2024;(6):10-17
Functional cyto­kine redu­ndancy in pregnancy. Russian Journal of Human Reproduction. 2024;(6):73-80
Resu­lts of clinical and immu­nomorphological analysis in chro­nic post-traumatic uveitis. Russian Annals of Ophthalmology. 2024;(6):39-44
Nottingham Prognostic Index rela­tion to cyto­kine-producing tumor mole­cular subtypes in breast cancer. Russian Journal of Preventive Medi­cine. 2025;(1):63-68
Abstract:

Objective. To explore the expression of Sema4D, CD72 receptor and a role of Sema4D-CD72 signal in the control of immunocompetent cell function in remitting-relapsing multiple sclerosis (RRMS). Material and methods. Fifty-two patients with RRMS diagnosis according to 2010 revised McDonald’s criteria were studied. The control group included 24 healthy people. A flow cytometry method was used to measure the expression of semaphorin Sema4D by T-lymphocytes of peripheral blood, expression of CD72 receptor by B-lymphocytes, percentage of cells containing pro- and anti-inflammatory cytokines. The level of soluble Sema4D (sSema4D) was evaluated by ELISA. Results. The level of Sema4D expression on T-lymphocytes (Mean Fluorescence Intensity — MFI) prevailed in cell subpopulations in patients with RRMS compared with the control group. Characteristics of membrane and sSema4D correlate with clinical presentations of the autoimmune disease. An increase in sSema4D level during cell cultivation was identified in RRMS patients. The results show the involvement of Sema4D in the hyperactivation of B-cell-mediated immunity through CD72 receptor and induction of proinflammatory cytokine synthesis. Conclusion. RRMS is associated with elevated expression of Sema4D in the immune system. Membrane and sSema4D involved in the pathological process in RRMS. The authors suggest several mechanisms of the involvement of semaphorin and its receptor in the pathogenesis of RRMS: the direct damage of nervous tissues by sSema4D penetrated through the blood brain barrier disrupted in RRMS or by membrane Sema4D due to the infiltration of the central nervous system by T-lymphocytes and hyperactivation of B-cell-mediated immunity.

Keywords:

remitting-relapsing multiple sclerosis
autoimmune pathology
peripheral immune system
semaphorin Sema4D
T-lymphocytes
B-lymphocytes
soluble Sema4D
receptor CD72
Sema4D-CD72-signal
cytokines

Authors:

Danchenko I.Yu.

Vagner Perm State Medical University

Baidina T.V.

Vagner Perm State Medical University

Kuklina E.M.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Trushnikova T.N.

Wagner Perm State Medical University

Nekrasova I.V.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Close metadata

References:

  1. Boiko AN, Boiko OV, Gusev EI. The choice of the optimal drug for pathogenic treatment of multiple sclerosis: a current state of the problem (a review). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;114;10(2):77-91. (In Russ.)
  2. Stolyarov ID. The modern methods of diagnostics and treatment of multiple sclerosis. Vestnik Roszdravnadzora. 2010;4:64-67. (In Russ.)
  3. Karakulova YuV, Zhelnin AV, Trushnikova TN. Epidemiology and geography of multiple sclerosis in the Perm region. Vestnik Roszdravnadzora. 2013;2:43-45. (In Russ.)
  4. Chapoval SP, Vadasz Z, Chapoval AI, Toubi E. Semaphorins 4A and 4D in chronic inflammatory diseases. Inflamm Res. 2017;66:111-117. https://doi.org/10.1007/s00011-016-0983-5
  5. Kumanogoh A, Marukawa S, Suzuki K, Takegahara N, Watanabe C, Ch’ng E, Ishida I, Fujimura H, Sakoda S, Yoshida K, Kikutani H. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature. 2002;419(6907):629-633. https://doi.org/10.1038/nature01037
  6. Koda T, Okuno T, Takata K, Honorat JA, Kinoshita M, Tada S, Moriya M, Sakoda S, Mochizuki H, Kumanogoh A, Nakatsuji Y. Sema4A inhibits the therapeutic effect of IFN-β in EAE. J Neuroimmunol. 2014;268(1-2):43-49. https://doi.org/10.1016/j.jneuroim.2013.12.014
  7. De Wit J. Role of semaphorins in the adult nervous system. Prog Neurobiol. 2003;71(2-3):249-267. https://doi.org/10.1016/j.pneurobio.2003.06.001
  8. Hsieh HH, Chang WT, Yu L, Rao Y. Control of axon-axon attraction by Semaphorin reverse signaling. Proc Natl Acad Sci USA. 2014;111(31):11383-11388. https://doi.org/10.1073/pnas.1321433111
  9. Zhang Y, Liu B, Ma Y, Jin B. Sema 4D/CD100-plexin B is a multifunctional counter-receptor. Cell Mol Immunol. 2013;10(2):97-98. https://doi.org/10.1038/cmi.2012.65
  10. Kumanogoh A, Suzuki K, Ch’ng E, Watanabe C, Marukawa S, Takegahara N, Ishida I, Sato T, Habu S, Yoshida K, Shi W, Kikutani H. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J Immunol. 2002;169(3):1175-1181. https://doi.org/10.4049/jimmunol.169.3.1175
  11. Giraudon P, Vincent P, Vuaillat C, Verlaeten O, Cartier L, Marie-Cardine A, Mutin M, Bensussan A, Belin MF, Boumsell L. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol. 2004;172(2):1246-1255. https://doi.org/10.4049/jimmunol.172.2.1246
  12. Wang X, Kumanogoh A, Watanabe C, Shi W, Yoshida K, Kikutani H. Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses. Blood. 2001;97(11):3498-3504. https://doi.org/10.1182/blood.v97.11.3498
  13. Kumanogoh A, Kikutani H. The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol. 2001;22(12):670-676. https://doi.org/10.1016/s1471-4906(01)02087-7
  14. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell. 1999;99(1):71-80. https://doi.org/10.1016/s0092-8674(01)00216-1
  15. Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T, Matsumoto M, Yoshida K, Yakura H, Pan C, Parnes JR, Kikutani H. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity. 2000;13(5):621-631. https://doi.org/10.1016/s1074-7613(00)00062-5
  16. Braley TJ, Segal BM. B-cell Targeting Agents in the Treatment of Multiple Sclerosis. Current Treatment Options in Neurology. 2013;15(3):259-269. https://doi.org/10.1007/s11940-013-0232-y
  17. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
  18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;6(4):907-911. https://doi.org/10.1212/wnl.46.4.907
  19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. https://doi.org/10.1212/wnl.33.11.1444
  20. Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol. 2000;7(3):281-289. https://doi.org/10.1016/s0165-5728(98)91768-4
  21. Baidina TV, Kuklina EM, Trushnikova TN, Pichkaleva YuA, Sursyakova NV, Danchenko IYu, Medvedeva EL, Foteeva AV. Pathogenetic and clinical peculiarities of disseminated sclerosis. Perm Medical Journal. 2016;33(4):17-22. (In Russ.)
  22. Kuklina EM, Baidina TV, Danchenko IYu, Nekrasova IV. Semaforin Sema4D in the immune system in multiple sclerosis. Bulletin of Experimental Biology and Medicine (English version). 2014;157(2):198-201. (In Russ.) https://doi.org/10.1007/s10517-014-2533-x
  23. Adachi T, Flaswinkel H, Yakura H, Reth M, Tsubata T. The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol. 1998;160(10):4662-4665. https://doi.org/10.1016/s0165-5728(98)91768-4
  24. Kumanogoh A, Kikutani H. Biological functions and signaling of a transmembrane semaphorin, CD100/Sema4D. Cell Mol Life Sci. 2004;61(3):292-300. https://doi.org/10.1007/s00018-003-3257-7
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.